What Abdi Ibrahim Pharmaceuticals does

Abdi Ibrahim is Turkey's largest pharmaceutical company by sales volume, holding the market leadership position since 2002 (24 consecutive years). Founded in 1912 as a pharmacy in Istanbul and 100% Turkish-capital-controlled by the Barut family (third generation), the company manufactures 255+ brands and 530+ products across CNS, respiratory, cardiovascular, oncology, consumer health, and biosimilar therapeutic areas. Its manufacturing footprint spans chemical, biotech, and generic drug production across solid forms, liquids, semi-solids, hormones, high-potency compounds, dry powder inhalers, and sterile ophthalmology products.

The vertically integrated production base is anchored by the Esenyurt Production Complex (174,600 m², 700 million boxes/year capacity) and the AbdiBio biotechnology facility (Turkey's largest, producing monoclonal antibody biosimilars including Trastuzumab/Canhera for metastatic breast cancer). International plants operate via majority-owned Kazakhstan subsidiary AIGP (24M boxes/year) and Algeria subsidiary AIRP (51M boxes/year). The company operates Turkey's first accredited pharmaceutical R&D Center, with capabilities in inhalation technology, nanotechnology, bioequivalence studies, and CTD dossier preparation.

Abdi Ibrahim generates revenue through three primary streams: (1) prescription and OTC pharmaceutical sales distributed via a 2,400-person sales force through Turkey's pharmacy network; (2) contract manufacturing for global pharmaceutical companies using EU-GMP-certified capacity; and (3) in-licensing and co-marketing arrangements with 30+ international partners. Customers span healthcare providers, hospitals, pharmacies, and end consumers, with products reaching 70+ countries across Europe, Africa, Asia, and North America. Strategic ESG initiatives include the ODAK localization initiative, 100% renewable electricity at the Esenyurt complex since 2020, and three consecutive years on the CDP Climate A List.

Name

Abdi Ibrahim Pharmaceuticals

Legal name

Abdi İbrahim İlaç Sanayi ve Ticaret Anonim Şirketi

Website

https://abdiibrahim.com.tr

Company type

Private

Founded year

1912

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Abdi Ibrahim is Turkey's largest pharmaceutical manufacturer (founded 1912, Barut family-controlled), producing 255+ brands and 530+ products across CNS, oncology, respiratory, and consumer health categories via its Esenyurt complex, AbdiBio biotech facility, and international plants in Kazakhstan and Algeria.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Specialty Pharmaceutical Distributors (HLAIAJAB)

akta.pro secondary industries

Hospital & Health-System Pharmaceutical Distributors (HLAIAJAD), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Respiratory & Allergy Pharmaceuticals (HLAIAAAH)

Keywords

• Pharmaceutical manufacturing
• Prescription medicines
• Biotechnology drugs
• Generic pharmaceuticals
• Contract manufacturing

Headquarters

HQ city

Maslak

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical Sales (Prescription & OTC): Revenue generated from sale of prescription pharmaceutical products and over-the-counter consumer health products. The company markets 255+ brands and 530+ products across therapeutic areas including CNS, cardiovascular, oncology, respiratory, and consumer health.
2. Contract Manufacturing Services: Abdi Ibrahim provides production services to international pharmaceutical companies utilizing its EU-approved GMP facilities with 630 million box production capacity. The company offers manufacturing for solid, liquid, semi-solid, and biotechnology products.
3. In-licensing & Co-Marketing: The company generates revenue through in-licensing and co-marketing arrangements with 30+ international licensors, bringing global pharmaceutical products to Turkish and international markets.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Abdi Ibrahim Pharmaceuticals manufactures, markets, and distributes a broad portfolio of over 255 brands and 530+ pharmaceutical products across therapeutic areas including central nervous system, cardiovascular, oncology, respiratory, consumer health, and general treatments. The company operates production facilities in Turkey, Kazakhstan, and Algeria, and offers contract manufacturing services to international pharmaceutical companies. In addition to branded prescription drugs and OTC consumer health products, Abdi Ibrahim produces biosimilars at its AbdiBio biotechnology facility.

Product overview

Abdi Ibrahim Pharmaceuticals is Turkey's leading pharmaceutical company (sector leader since 2002) offering a broad portfolio of over 255 brands and 530+ products across therapeutic areas including general treatments, central nervous system, respiratory, consumer health, and specialized treatments. The product portfolio includes branded prescription pharmaceuticals (e.g., Abetyl for prostate cancer, Abilify for CNS disorders, Canhera/Trastuzumab biosimilar from AbdiBio for breast cancer), consumer health OTC products (Bruno Baby, YouPlus supplements, Ella emergency contraception, Melatonin), respiratory products (Brequal, Fastair, Coriva inhalers), and general treatments spanning analgesics (Apranax, Contramal, Diclomec), anticoagulants (Apixenta, Ecopirin), and anti-infectives (Diafuryl, Enzaflu). The company operates dedicated production facilities in Turkey (Esenyurt, AbdiBio biotech center, Technologistic Center, R&D Center), Kazakhstan (Abdi Ibrahim Global Pharm/AIGP), and Algeria (Abdi Ibrahim Remede Pharma/AIRP), with international partnerships including Abdi Ibrahim Otsuka (with Japan's Otsuka Pharmaceutical) and OM Pharma (Swiss biotech). The portfolio is organized across treatment categories: General Treatments, Central Nervous System, Otsuka partnership products, Special Treatments, Respiratory, Non-Promoted Products, and Consumer Health.

Differentiator

Problem solved

Functional benefit

Brands

• AbdiBio: Turkey's largest biotechnological drug production facility and subsidiary focused on biopharmaceutical products including oncology, diabetes, rheumatology, CNS, ophthalmology and hematology treatments.
• Abdi İbrahim Otsuka
• Abdi İbrahim Global Pharm
• Abdi İbrahim Remede Pharma
• Abdi İbrahim Vakfı
• ODAK

Products and services

• Canhera (Trastuzumab) Trastuzumab lyophilized powder vial for metastatic breast cancer treatment; Turkey's first biosimilar product from AbdiBio, available in 150mg vial formulation.
• Abetyl Abiraterone acetate tablet for prostate cancer treatment, available in 250mg and 500mg formulations.
• Abilify (Aripiprazole) Aripiprazole-based product line for central nervous system disorders, including oral solution, tablets (1mg/5mg/10mg/15mg/30mg), and Abilify Maintena long-acting injectable; marketed through the Abdi Ibrahim Otsuka joint venture.
• Bevax (Bevacizumab) Bevacizumab IV infusion concentrate for cancer treatment, available in 100mg/4mL and 400mg/16mL vials.

Quantifiable outcome

• 24 consecutive years as Turkey's pharmaceutical market leader (since 2002)
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• OM PharmacoreStrategic or Co-development Partner · 1 September 2020Abdi Ibrahim acquired 28.5% stake in OM Pharma (Switzerland) in September 2020, becoming the first and only Turkish pharmaceutical company to have strategic partnership with a European pharmaceutical company. OM Pharma is an 89-year-old biotechnology pharmaceutical company based in Switzerland.
• Remede Pharma (Algeria)coreStrategic or Co-development Partner · 1 January 2014Abdi Ibrahim acquired 49% stake in Remede Pharma in 2014, establishing Abdi Ibrahim Remede Pharma (AIRP). Algeria's most modern pharmaceutical factory began production in 2017 with 51 million box/year capacity. Portfolio covers urology, CNS, respiratory, metabolism, and iron deficiency treatments.
• Otsuka PharmaceuticalcoreStrategic or Co-development Partner · 1 January 2012Joint venture (50-50) established in 2012 between Abdi Ibrahim and Japan's Otsuka Pharmaceutical. Abdi Ibrahim Otsuka (AIO) focuses on CNS, cardiovascular diseases, and rare diseases like polycystic kidney disease. Operates in Turkey, Singapore, and Tunisia with 70 employees.
• Global Pharm (Kazakhstan)coreStrategic or Co-development Partner · 1 January 2012Abdi Ibrahim acquired 60% stake in Kazakhstan's leading pharmaceutical manufacturer Global Pharm in 2012, establishing Abdi Ibrahim Global Pharm (AIGP). The facility began operations in December 2015 with 24 million box/year capacity and 300 employees.
• Sürdürülebilirlik Adımları Derneği (SADE)minorStrategic or Co-development PartnerPartnership with Sustainability Steps Association (SADE) for the ODAK localization project implementation.
• TÜBİTAK (Various Programs)coreStrategic or Co-development PartnerCollaboration with TÜBİTAK through multiple programs: TÜBİTAK-2244 (Industry Doctorate Program with 12 doctoral students), TÜBİTAK-TEYDEB for product development, and TÜBİTAK-ARDEB for university-industry research partnerships.

Scale indicators7 records

Recent moves10 records

Expansion highlights5 records

Direct peers

• Hikma Pharmaceuticals: Jordan-headquartered, UK-listed specialty and generics manufacturer with a multi-country manufacturing footprint and strong presence across the MENA region. Highly comparable to Abdi İbrahim in scale, regional dominance, branded-plus-generic mix, and biosimilar/specialty ambitions.
• STADA Arzneimittel: German mid-tier generics and specialty pharma with a broad European footprint, multiple production sites, and biosimilar exposure. Closest European analog to Abdi İbrahim in product breadth, distribution depth, and mid-size category positioning.
• Krka: Slovenian pharmaceutical manufacturer with broad generic portfolio and growing specialty footprint across CEE, Russia/CIS and Western Europe. Comparable in size, vertically integrated model, and emphasis on accessibility across emerging European and CIS markets.
• Gedeon Richter: Hungarian pharmaceutical company combining branded generics, specialty (CNS/women's health), and biosimilars, with CEE origins and increasing Western European presence. Comparable in therapeutic breadth, CEE base, and biosimilar/biotech strategy.
• Polpharma: Polish pharmaceutical manufacturer with broad generics portfolio and CEE/CIS distribution focus. Comparable in regional dominance, vertically integrated generics/specialty manufacturing, and mid-tier European positioning.
• Almirall: European specialty pharma focused on dermatology and other specialty therapeutics with a broad branded portfolio. Comparable therapeutic-area specialization and branded-versus-generic balance at similar mid-cap scale.
• Recordati: Italian mid-cap pharma with a hybrid specialty and rare-disease portfolio, including its own manufacturing and growing presence in CEE and emerging markets. Comparable in branded specialty focus and in-licensing model.
• Aurobindo Pharma: Indian vertically integrated generic manufacturer with growing specialty, biosimilar, and injectables franchises and broad international distribution. Comparable as an integrated generics manufacturer scaling into specialty/biosimilars across emerging markets.

Broad incumbents

• Sandoz: Recently independent global leader in generic and biosimilar medicines, spun out of Novartis. Larger in absolute scale but the clearest comparable for Abdi İbrahim's stated biosimilar and generics globalization strategy.
• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with material specialty (CNS, respiratory) and biosimilar exposure. Much larger and more globally diversified, but a useful upper-bound reference on the generic-plus-specialty model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/abdiibrahimilac
• YouTubeyoutube.com/user/abdiibrahimilac
• Facebookfacebook.com/abdiibrahimilac
• LinkedInlinkedin.com/company/abdi-ibrahim-pharmaceuticals
• Instagraminstagram.com/abdiibrahimilac/?hl=tr

Compliance15 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abdi Ibrahim Pharmaceuticals